The Italian pharma will gain access to Gossamer Bio’s candidate seralutinib, which reached its primary endpoint in a Phase II ...

One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates ...

Shares in Acceleron have been grown by the third in the last month, and closed on Friday at almost $168, not far off its 52-week high of $174. Image Phil Taylor ...

Merck agreed to buy Acceleron Pharma Thursday in a deal that values the rare drug specialists at around $11.5 billion. Merck will pay $180 per share for Cambridge, Massachusetts-based Acceleron ...

After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far.

Acceleron Bank Revolutionizes International Payments With NudgeConvert: Empowering Community Banks and Credit Unions To Generate Non-Interest Income. WHITE RIVER JUNCTION, VT / ACCESSWIRE / March ...

In this photo illustration, the Merck Sharp and Dohme logo is displayed on a ... [+] smartphone screen. (Photo Illustration ...

In Merck’s quarterly conference call on Thursday, it took CEO Rob Davis less than a minute to tout newly approved pulmonary ...

At the time of its Acceleron buyout, the company projected Winrevair, also known as sotatercept, would compete in a PAH drug ...

Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming ...